Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 746

Sort by

Sort Order Select

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

Aurelie Baudet, PhD, Karolina Paulina Komorowska, PhD, Hultmark Simon, MS, Marcus Järås, PhD, Marion Chapellier, PhD, Gunnar Juliusson, MD PhD, Mattias Magnusson, PhD

Blood (2019) 134 (Supplement_1): 2466.

https://doi.org/10.1182/blood-2019-122661

Published: 2019

Journal Articles

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

Blood (2019) 134 (Supplement_1): 2375.

https://doi.org/10.1182/blood-2019-129200

Published: 2019

Journal Articles

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Amandeep Kaur, PhD, Katherine M Hannan, PhD, Samina Nazir, MSc, Kylee H Maclachlan, FRACP,FRCPA, Gretchen Poortinga, PhD, Si Ming Man, PhD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Ross D Hannan, PhD, Elizabeth E. Gardiner, PhD

Blood (2019) 134 (Supplement_1): 2360.

https://doi.org/10.1182/blood-2019-121713

Published: 2019

Journal Articles

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Melissa Castiglione, BS, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 2485.

https://doi.org/10.1182/blood-2019-131074

Published: 2019

Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP

Blood (2019) 134 (Supplement_1): 5598.

https://doi.org/10.1182/blood-2019-132087

Published: 2019

Journal Articles

The Absolute Count of Circulating, Classical, CD14 ++ /CD16 - Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML)

Matthieu Jestin, Sihem Tarfi, PharmD, Bouchra Badaoui, PharmD, Nicolas Freynet, PharmD, Ivan Sloma, PharmD,PhD, Margot Morabito, Sébastien Maury, MD PhD, Pierre Fenaux, MD PhD, Eric Solary, MD PhD, Dorothée Selimoglu-Buet, PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 4242.

https://doi.org/10.1182/blood-2019-121794

Published: 2019

Journal Articles

Molecular Analysis in Patients with Idiopathic Erythrocytosis

Katarzyna Aleksandra Jalowiec, Naomi A. Porret, PhD, Raphael Joncourt, Alicia Rovo

Blood (2019) 134 (Supplement_1): 2230.

https://doi.org/10.1182/blood-2019-128169

Published: 2019

Journal Articles

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

Caitlin R. Rausch, PharmD, Courtney D. DiNardo, MDMSc, Abhishek Maiti, MBBS, Nadya Jammal, PharmD, Tapan M. Kadia, MD, Kayleigh Marx, PharmD, Gautam M. Borthakur, MD, J Michael Savoy, PharmD, Naveen Pemmaraju, MD, Adam Dipippo, PharmD, Naval G. Daver, MD, Serena Chew, PharmD, Koji Sasaki, MD, Ghayas C. Issa, MD, Kiran Naqvi, MDMPH, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2640.

https://doi.org/10.1182/blood-2019-131988

Published: 2019

Journal Articles

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Hongyan Tong, Docter, Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, MD, Shengyun Lin, Yuefeng Zhuang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 2594.

https://doi.org/10.1182/blood-2019-127675

Published: 2019

Journal Articles

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2647.

https://doi.org/10.1182/blood-2019-122477

Published: 2019

Journal Articles

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Keiji Minakawa, Koki Ueda, MD PhD, Osamu Nakajima, Tetsuro Yokokawa, MD, Yusuke Kinishima, MD, Tomofumi Misaka, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yasuchika Takeishi, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2019) 134 (Supplement_1): 2964.

https://doi.org/10.1182/blood-2019-124575

Published: 2019

Journal Articles

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Tobias Ronny Haage, MD, Andreas Johann Müller, Priyadharshini Arunachalam, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2965.

https://doi.org/10.1182/blood-2019-122660

Published: 2019

Journal Articles

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Peter Müller, PhD, Bärbel Edelmann-Stephan, PhD, Fabian Richter, PhD, Klaus Pfizenmaier, PhD, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2966.

https://doi.org/10.1182/blood-2019-127997

Published: 2019

Journal Articles

The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia

Rong Fu, Jr., PhD, Shaoxue Ding, MD, Chunyan Liu, Bingnan Liu, Hui Liu, Liu Zhaoyun, Tong Chen, MD, Tian Zhang, Zonghong Shao, MD, Ting Wang

Blood (2019) 134 (Supplement_1): 3747.

https://doi.org/10.1182/blood-2019-127769

Published: 2019

Journal Articles

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 3750.

https://doi.org/10.1182/blood-2019-132220

Published: 2019

Journal Articles

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia

Keith W. Pratz, MD, Andrew H. Wei, Daniel A Pollyea, MD, Brian A Jonas, MD PhD, Walter Fiedler, MD, Christian Recher, MD PhD, Wan-Jen Hong, MD, Jalaja Potluri, MD, Catherine Miller, PharmD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3897.

https://doi.org/10.1182/blood-2019-127423

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

NARROW

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding

The Ribosomal Biogenesis Inhibitor CX-5461 Is an Anti-Cancer Therapeutic That Increases Platelet Count in Mice and in Humans

Cell Competition and Microenvironment in the Development of Myeloproliferative Neoplasms

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

The Absolute Count of Circulating, Classical, CD14 ++ /CD16 - Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML)

Molecular Analysis in Patients with Idiopathic Erythrocytosis

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only